Objective. To evaluate, from a societal perspective, the incremental cost-effectiveness of withdrawing tumor necrosis factor inhibitor (TNFi) treatment compared to continuation of these drugs within a 1-year, randomized trial among rheumatoid arthritis patients with longstanding, stable disease activity or remission.
Objective. To evaluate, from a societal perspective, the incremental cost-effectiveness of withdrawing tumor necrosis factor inhibitor (TNFi) treatment compared to continuation of these drugs within a 1-year, randomized trial among rheumatoid arthritis patients with longstanding, stable disease activity or remission.
Methods. Data were collected from a pragmatic, open-label trial. Cost-utility analysis was performed using the nonparametric bootstrapping method, and a cost-effectiveness acceptability curve was constructed using the net-monetary benefit framework, where a willingness-to-accept threshold (WTA) was defined as the minimal cost saved that a patient accepted for each quality-adjusted life year (QALY) lost.
Results. A total of 531 patients were randomized to the stop group and 286 patients to the continuation group. Withdrawal of TNFi treatment resulted in a >60% reduction of the total drug cost, but led to an increase of $ 30% in other health care expenditures. Compared to continuation, stopping TNFi resulted in a mean yearly cost saving of €7,133 (95% confidence interval [95% CI] €6,071, €8,234]) and was associated with a mean loss of QALYs of 0.02 (95% CI 0.002, 0.040). Mean saved cost per QALY lost and per extra flare incurred in the stop group compared to the continuation group was €368,269 (95% CI €155,132, €1,675,909) and €17,670 (95% CI €13,650, €22,721), respectively. At a WTA of €98,438 per QALY lost, the probability that stopping TNFi treatment is cost-effective was 100%.
Conclusion. Although an official WTA is not defined, the mean saved cost of €368,269 per QALY lost seems acceptable in The Netherlands, given existing data on willingness to pay.
Rheumatoid arthritis (RA) is a progressive, immune-mediated inflammatory disease that has a prevalence of~1% in developed countries (1) . The disease is characterized by synovial inflammation and with time may involve articular damage, disability, and extraarticular manifestations. Besides its negative impact on the health of individual patients, RA imposes a significant and increasing economic burden on health care systems and societies in the form of health care resource utilization and (paid) productivity loss (2) .
The main goal in the treatment of RA is to suppress inflammatory activity to control pain and prevent unfavorable outcomes such as structural damage and functional disability. Accumulating evidence suggests that optimal clinical outcomes may be achieved if treatment is started early and adjusted to reach predefined disease activity targets (3, 4) . The subpopulation of patients receiving biologic disease-modifying antirheumatic drugs (bDMARDs), including tumor necrosis factor inhibitors (TNFi), in this treat-to-target strategy has increased over time and accounted for up to 20% of the population of RA patients in various Western health care systems (5, 6) . Although it is widely believed that the introduction of bDMARDs has contributed to the overall improved clinical picture of severe RA, particularly in patients with methotrexate-refractory disease (7), their high cost has raised the question of whether bDMARDs could be discontinued in patients who achieve long-term, stable controlled disease, without negatively affecting their health (8) .
As health care budgets are limited and money can be spent only once, savings from stopping treatment with bDMARDs could be used to reinvest in other treatments or increase access to bDMARDs for a larger proportion of the RA patient population. The recently completed Potential Optimalisation of Expediency and Effectiveness of TNFi (POET) trial aimed to evaluate the clinical course of patients in whom TNFi treatment was withdrawn, compared to that of patients who continued to receive TNFi (9) . The results showed that patients who in whom TNFi treatment was withdrawn were >3 times as likely to experience a disease flare compared to patients who continued their TNFi treatment. However, disease control could typically be quickly regained upon TNFi restart. Although the withdrawal of TNFi is evidently associated with lower medication costs, this may be offset by higher non-drug-related health care costs or by lasting impact on patients' overall quality of life. From the health economic point of view, it is currently unclear whether the benefits of discontinuation of TNFi outweigh the harms. The present study aimed to evaluate, from a societal perspective, the 1-year trial-based cost utility and cost-effectiveness of withdrawing TNFi compared to continuation of these drugs in RA patients with longstanding stable disease, to inform rheumatologists and patients about balance between savings and health forgone.
PATIENTS AND METHODS
Study design and patients. The study outcomes and design of the POET study (NTR3112) are described in detail elsewhere (9) . Briefly, this pragmatic, open-label trial was performed at 47 rheumatology centers in The Netherlands and included 817 adult patients fulfilling the American College of Rheumatology 1987 classification criteria for RA (10) who were treated with TNFi for at least 1 year. In addition, patients met 1 of the following criteria: 1) Disease Activity Score in 28 joints (DAS28) <3.2 for at least 6 months preceding inclusion (n = 672) or 2) perceived by a rheumatologist as having remission or low disease activity for at least 6 months prior to inclusion, with DAS28 <3.2 at baseline and C-reactive protein level <10 mg/liter at least once in the 6-month period prior to inclusion (n = 145). Patients were randomized to either the stop group (n = 531) or the continuation group (n = 286). After inclusion, TNFi were withdrawn in the stop group but maintained in the continuation group. Any other treatment decisions were made by rheumatologists with their patient and continued unchanged as much as possible in both groups. The primary outcome measure of the study was occurrence of disease flares, defined as a DAS28 increase of ≥0.6 compared to baseline and a current DAS28 level of ≥3.2.
Follow-up procedures. Patients were assessed at baseline and at least once every 3 months thereafter, for a period of 1 year. At each visit, components of the DAS28, the Health Assessment Questionnaire (HAQ) disability index (DI) (11, 12) , and the EuroQol 5-domain 3-level (EQ-5D-3L) questionnaire (13) were evaluated, laboratory tests conducted, and patient-reported outcomes recorded. Patient-reported outcomes included adverse events, days of sick leave, and frequencies of health care resource utilization. Restart of a TNFi was allowed when a flare occurred; for ethical reasons this included cases where the patient's perception of a flare could not be objectively verified.
Health economic outcomes. At each visit, patients answered the EQ-5D-3L questionnaire and reported the frequencies of health care resource utilization and number of days of sick leave (in those with a paid job) during the past 3 months. The health care resource utilization included visits to rheumatologists and general practitioners, visits to nurse specialists, physiotherapists, and psychologists, numbers of diagnostic and laboratory tests, days in hospital, and hours of formal and informal care.
For each patient, the health utility at 3-month visits was computed using the Dutch tariffs for EQ-5D-3L (14), and quality-adjusted life years (QALYs) were computed as the area under the EQ-5D-3L curve. Nondrug direct costs were calculated based on patient-reported frequencies of health care resource utilization. The unit costs were retrieved from the Dutch Guideline for Economic Evaluations in Healthcare. Drug costs were calculated based on the doses of drug used and the medication prices. Indirect costs for those patients with a paid job were calculated using the friction-cost method with a 3-month friction period and were based on the number of hours absent from work and the average wage per hour for each age group and sex (15) . The unit costs and prices published before the current year (2016) were adjusted to the current year using the consumer price index for The Netherlands (16). Costs were not discounted because of the short time horizon of 12 months.
Statistical and cost-effectiveness analyses. Between 10% and 15% of observations contained missing values for costs or utilities (for details, see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40546/abstract). For the cost-effectiveness analysis, these were replaced with estimates using multiple imputation, as recommended by the International Society for Pharmacoeconomics and Outcomes Research for cost-effectiveness analysis alongside clinical trials (17) . For each of the 10 imputed data sets, cost-effectiveness analysis was performed using the nonparametric bootstrapping method (18) . Five thousand bootstrap samples were generated, from which the expected costs and QALYs over the 1-year follow-up in each treatment group and the ratios of incremental cost to incremental QALYs or flares (ICERs) were computed (19) . Manca et al recommended an adjustment of QALYs before calculation of ICERs when there was an imbalance in the mean baseline health utility between 2 trial arms (20) . Because mean baseline health utility and other patient characteristics in our study were almost equal between the stop and continuation groups, in the main analyses and presentation of the results we used QALYs and costs unadjusted for these negligible differences.
To examine the effect of QALYs and cost adjustment on ICERs, we used the regression-based method proposed by Manca et al (20) , in which linear regression models for patientspecific QALYs and costs were fitted to the observed data, with predictors for QALYs being treatment and baseline health utility, and predictors for costs being treatment, age, sex, disease duration, DAS28 score, and HAQ DI score. Then we used the coefficients for the treatment as the differential QALYs and costs for the adjustment. We applied a Box-Cox transformation for QALYs and a log transformation for costs to meet the assumptions of normal distribution and equal variance of the error term in the linear models (21) . The results were pooled across imputed data sets using Rubin's rules (22) to take into account the uncertainty introduced by the missing data. Because the distribution of costs was skewed, the "approximate bootstrap confidence" (ABC) algorithm (23) was used to estimate the confidence intervals (CIs), instead of the usual symmetric CI proposed by Rubin (22) . For each imputed data set, a confidence density curve was constructed for each of the outcome variables. The 10 confidence density curves were then combined by averaging the y-values to obtain the average density function, on which the 95% CIs were established by determining the areas under the curve that corresponded to 5% and 95% percentiles. For each imputed data set, a cost-effectiveness acceptability curve was constructed using the net-monetary benefit (NMB) framework (24) , where an expected NMB was calculated as the difference between the willingness-to-accept threshold (WTA) for each QALY lost multiplied by the mean QALYs ð E i Þ, and the mean cost obtained from each bootstrap replication 
RESULTS
Baseline characteristics were similar in both groups ( Table 1 ). The majority of the patients had longstanding, erosive disease and utility scores reasonably close to general population norms (25) . The sample was further characterized by low disease activity at baseline according to the DAS28, as per the inclusion criteria, and low disability according to HAQ DI scores.
Health outcomes. Mean DAS28 and HAQ DI scores in the continuation group were almost stable over time (Figure 1) , while in the stop group the mean DAS28 score increased from baseline to month 3 and then gradually decreased during the rest of the year, and the mean HAQ DI score slightly increased over time. Post hoc analyses revealed significant differences in DAS28 scores at all follow-up visits (P < 0.01), except baseline (P = 0.27). No significant difference in HAQ DI scores between the 2 groups at any time point was observed.
The percentages of patients with 1 or 2 flares within 12 months were 41.1% and 8.1% in the stop group and 15.4% and 1.4% in the continuation group, respectively. No patients and only 0.6% of patients had * RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide antibody; DAS28 = Disease Activity Score in 28 joints; HAQ = Health Assessment Questionnaire; EQ-5D-3L = EuroQol 5-domain 3-level measure; TNFi = tumor necrosis factor inhibitors.
3 flares in the continuation and stop groups, respectively. On average, within 12 months each patient experienced 0.59 flares (95% CI 0.53, 0.64) in the stop group and 0.18 flares (95% CI 0.13, 0.24) in the continuation group. Mean health utility in the continuation group slightly deteriorated during the first 6 months and then remained relatively stable during the rest of the year, while that in the stop group decreased within the first 3 months and then slightly increased until the end of the year (Figure 2 ). Except for month 3 (P = 0.0005), mean health utility was not significantly different at any time points between the 2 groups (P > 0.05).
Health care, medication, and sick leave costs and QALYs. Table 2 shows means and 95% CIs of nondrug health care costs, drug costs, and sick leave costs (in euros) and of QALYs per patient per year with the 2 treatment strategies. A detailed overview of health care resource utilization in each category at baseline and cumulative over 1 year, as well as the corresponding unit prices, is provided in Supplementary Tables 2-6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40546/abstract. Withdrawal of TNFi resulted in a >60% reduction of the total drug cost, but led to an increase of~30% for the other health care expenditures. Sick leave cost in the stop group was slightly lower than that in the continuation group, although the difference between the 2 groups was not significant. Since the cost of TNFi treatment was much larger than the increased expenditure in other cost components, the mean total cost incurred by each patient per year in the continuation group (€14,740 [95% CI €13,913, €15,676]) was almost double that in the stop group (€7,607 [95% CI €7,001, €8,261]). Mean QALY per patient in the stop and continuation groups was 0.79 (95% CI 0.781, 0.805) and 0.81 (95% CI 0.799, 0.829), respectively.
Incremental cost-effectiveness and uncertainty. An average patient in the stop group may save €7,133 (95% CI €6,071, €8,234) for society, but would lose 0.022 QALY (95% CI 0.002, 0.040) per year and experience 0.41 (95% CI 0.33, 0.48) more flares compared to an average patent in the continuation group. Mean saved cost per QALY lost and per extra flare incurred in the stop group compared to the continuation group was €368,269 (95% CI €155,132, €1,675,909) and €17,670 (95% CI €13,650, €22,721), respectively. When QALYs and costs were adjusted for differences in baseline health utility and patient characteristics, mean saved cost per QALY lost in the stop group compared to the continuation group (€371,457 [95% CI €156,291, €1,736,887]) was slightly higher than that when no adjustment was made. Because the difference in mean sick leave costs between the 2 groups was very small, mean costs saved from the health care perspective, per QALY lost (€366,642 [95% CI €152,396, €1,662,057]) and per flare increase (€17,587 [95% CI €13,575, €22,642]) were similar to those from the societal perspective. Hereafter, we focused on the outcomes and interpretation from the societal perspective.
A scatter plot of the incremental mean costs and QALYs resulting from 50,000 bootstrapped replications for 10 imputed data sets is provided in Figure 3 . All differences in mean costs were negative. Approximately 1.5% of all data points fell in the southeast quadrant (i.e., saved cost with increased QALYs), indicating that the probability of TNFi withdrawal being cost-effective at any level of WTA is negligible. At WTAs of €330,450 and €98,438, the probabilities of TNFi withdrawal being cost-effective were 0.5 and 1.0, respectively (Figure 4) . If stopping TNFi is considered as the baseline comparator, it was almost certain that the continuation of TNFi was not cost-effective at a willingness-to-pay (WTP) of €100,000 per QALY gained.
DISCUSSION
Our analysis shows that stopping TNFi treatment in RA patients with stable controlled disease (remission or low disease activity) can save considerable cost, but results in a small QALY loss. At the beginning of this century, TNFi were developed, studied, and introduced to control inflammatory disease activity in patients with RA. Despite increasing budget impact over the first 15 years since the introduction of these drugs, evidence regarding the possibility of discontinuing TNFi in the maintenance phase is still sparse. Therefore, patients are frequently kept on TNFi treatment indefinitely. Up to now, TNFi have been recommended in most of the developed countries for management of RA and reimbursed for patients with persistently high disease activity despite adequate treatment with at least 2 conventional synthetic DMARDs (csDMARDs) (26) (27) (28) (29) . These recommendations were predominantly based on evidence of the favorable cost-effectiveness ratio of TNFi therapy compared to csDMARDs in patients with severe disease. For instance, a recent systematic literature review on economic aspects of treatment with TNFi to inform clinical recommendations by the European League Against Rheumatism showed that the incremental cost of the use of a TNFi after failure of 2 csDMARDs per QALY gain was <€60,000 (conversion applied) in 14 of 18 studies (30) . Regardless of the majority of studies with outcomes in favor of the use of TNFi in this population, concerns continue to be raised about * QALYs = quality-adjusted life years; csDMARD = conventional synthetic disease-modifying antirheumatic drug; TNFi = tumor necrosis factor inhibitor; ICER = incremental cost-effectiveness ratio. 
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the substantial impact of TNFi therapy on the health care budgets, owing to the high prices of these drugs. For economic reasons, withdrawal of TNFi treatment has therefore been considered in patients with sustained low disease activity.
To date, approximately a dozen studies examining the effects of discontinuing TNFi treatment on clinical outcomes have been published (9, (31) (32) (33) (34) (35) . Due to the heterogeneity in study designs, characteristics of patients, definitions of low disease activity, and criteria for restarting TNFi therapy when failure was observed, the results between studies differed remarkably; the proportions of patients whose disease remained in remission or with low disease activity after discontinuation of TNFi ranged from 0% to 33% at 7 months, and from 13% to 80% at 12 months (32) . Despite the fact that high treatment costs are a frequently cited motivation to conduct such studies, unfortunately no reports of previous discontinuation studies addressed preference-based health valuation such as the EQ-5D or health care costs, which are important to inform health policy decisions.
In the present study, we showed that the mean health utility did not significantly differ over time between patients in the stop and continuation groups, except for the first follow-up point after baseline. These results suggest that discontinuing TNFi treatment in patients with long-term stable disease is a strategy that over the course of 1 year is associated with considerable saved cost and negligible loss of quality of life. Very similar conclusions were reached in the Dose Reduction Strategy of Subcutaneous TNF inhibitors down-titration study, in which it was found that when using a TNFi down-titration approach guided by disease activity, an amount of €390,493 could be saved for each QALY lost, compared to continued tight control treatment. Together, these findings suggest significant potential for disinvestment decisions (i.e., to stop subsidizing therapies that are not cost-effective) (36) . This could potentially free up resources that could be reallocated to other more cost-effective interventions. One way to do this would be to look for scope for implementing other more cost-effective interventions for the patients formerly receiving TNFi, as any improvement in their health status could offset the loss in QALYs due to discontinuation. Such an approach would avoid having to make trade-offs involving reducing the health of patients with RA.
While there is no explicit WTA threshold that could be used to judge whether or not TNFi should be discontinued, it is useful to consider the threshold for WTP, which is suggested to be between €20,000 and €73,000 per QALY in The Netherlands (37) . The estimated saving per QALY lost of €368,269 is much higher than the maximal bound of this threshold range, suggesting that it would be cost-effective to discontinue TNFi in the maintenance phase while the patients are in a state of low disease activity or remission. Adjustment of QALYs and costs for differences in baseline health utility and patient characteristics resulted in a slightly higher saving than the above-mentioned value, which increases the likelihood that stopping TNFi is cost-effective.
Our study has strengths and weaknesses. It is based on the largest randomized controlled trial on discontinuing TNFi in RA patients with stable low disease activity, with high-quality data owing to a strictly electronic data collection protocol. Generalizability of the results to the overall population of patients withdrawing from TNFi is probably high, since our study was based on a pragmatic trial with relatively few inclusion and exclusion criteria being maintained during the recruitment. We used advanced methods, i.e., a combination of multiple imputation, bootstrap, and ABC algorithm to capture the uncertainty surrounding the study results. However, our findings on the cost-effectiveness of stopping TNFi are valid only for an intervention duration of 12 months. Studies on the WTA thresholds in patients with RA are important to support decision making. Since patients with different disease durations and numbers of failed TNFi may respond differently to the discontinuation of the current TNFi, more research on response to discontinuation is needed.
In conclusion, stopping TNFi treatment in RA patients with stable low disease activity, on average, was associated with a cost saving of €7,133, a loss of 0.022 QALYs, and an increase of 0.41 flares per patient per year. Although an official WTA threshold is not available, we found that the mean saved cost of €368,269 per QALY lost would be cost-effective in The Netherlands, given existing data on the WTP and the WTA:WTP ratio. If the WTA threshold is €100,000, the probability that stopping TNFi is cost-effective is approximately 1.
